NewsResearchStill Time To Participate In UK Medical Cannabis Trial

Still Time To Participate In UK Medical Cannabis Trial

-

EUROPE’S largest ever medical cannabis trial is still recruiting patients as it looks to gather further evidence to support its wider adoption.

Known as Project 21, the two-year trial was launched by Britain’s former Drugs Czar Prof David Nutt. He is seeking to recruit 20,000 patients.

Project 21’s partners include the United Patients Alliance and The Royal College of Psychiatrists (RCP), with the aim of creating the largest European medical cannabis body of evidence.

It is being backed by three medical cannabis businesses – Italian company Althea and UK, Firms Alta-Flora and Canuba – who will supply subsidised cannabis medicine.

The trial will focus on a number of conditions including; chronic pain, epilepsy, multiple sclerosis, post-traumatic stress disorder, Tourette’s syndrome, anxiety disorder or who have had a history of substance misuse.

Patients Are Forced to Break Law

Prof Nutt stated that up until 1971 cannabis had been used as a medicine in the UK for over a century before ‘it was banned for political reasons’

“Since then hundreds of thousands of patients have been forced to break the law to get a treatment that most find preferable to their previous prescription medicines,” he said.

He said Project 21 will provide a ‘solid clinical database from which experience of and confidence in, medical cannabis prescribing will develop, providing a foundation for other medical prescribers to build on’.

Professor Wendy Burn, the RCP president  said it hopes the trial will ‘address the paucity of evidence’ for the use of cannabis-based medicine.

Dr Arun Bhaskar, President of the British Pain Society said some 28m people in the UK will at some stage, suffer from chronic pain.

“Data from several countries reveal that medical cannabis have benefited several thousands of patients,”he added.

Prof Nutt, dismissed by the UK Government for saying alcohol and tobacco are more dangerous to health than ecstasy, LSD and cannabis, went on to form Drugs Science – an independent, science-led drugs charity.

For information on how to participate in the trial visit: https://drugscience.org.uk/project-twenty21/


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Germany’s ‘KanaVape’ Moment As Police And Courts Crackdown On ‘Narcotic’ Hemp & CBD

TWO senior figures in the European cannabis industry are leading the fight against over-zealous German law enforcement in a...

UK CBD Consumption To Switch From Oils To Capsules – As New Research Estimates Market Value At £690m

CAPSULES are set to replace oils as the preferred method of CBD consumption - as new research show the...

Crowdfunding: An Emerging Capital Greenhouse For The Cannabis Industry

ALPHAGREEN is expected to hit close to the £2m crowdfunding mark on the Seedrs platform by mid-May – double...

Former JP Morgan Banker Lands Two UK Cannabis Jobs

A VETRAN of American investment bank JP Morgan has entered the burgeoning field of cannabis with appointments to two...

Europe’s Hemp Pioneer Posts Record Results With CBD, Construction And Car-Making To The Fore

EUROPEAN pioneer HempFlax has posted record annual results with revenues up 43% to €14.5m (£12.5m) as it returned a...

Sales Up Sharply At Sativa Wellness But Operational Costs Lead to £4.5m Loss

BRITISH CBD firm Sativa Wellness saw annual sales rise by over one-third in an eventful year which saw it...

Must read

Germany’s ‘KanaVape’ Moment As Police And Courts Crackdown On ‘Narcotic’ Hemp & CBD

TWO senior figures in the European cannabis industry are...

You might also likeRELATED
Recommended to you